MD3341G2 - Method of treating the organic central nervous system lesions to infants - Google Patents

Method of treating the organic central nervous system lesions to infants Download PDF

Info

Publication number
MD3341G2
MD3341G2 MDA20060252A MD20060252A MD3341G2 MD 3341 G2 MD3341 G2 MD 3341G2 MD A20060252 A MDA20060252 A MD A20060252A MD 20060252 A MD20060252 A MD 20060252A MD 3341 G2 MD3341 G2 MD 3341G2
Authority
MD
Moldova
Prior art keywords
treatment
intramuscularly
week
course
injections
Prior art date
Application number
MDA20060252A
Other languages
Romanian (ro)
Russian (ru)
Other versions
MD3341F1 (en
Inventor
Светлана ХАДЖИУ
Original Assignee
Светлана ХАДЖИУ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Светлана ХАДЖИУ filed Critical Светлана ХАДЖИУ
Priority to MDA20060252A priority Critical patent/MD3341G2/en
Publication of MD3341F1 publication Critical patent/MD3341F1/en
Publication of MD3341G2 publication Critical patent/MD3341G2/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention refers to medicine, neurology, pediatrics and is meant for treatment of organic central nervous system lesions to infants.The method, according to the invention, consists in that the patient is administered Cerebrum Compositum intramuscularly for 0,6…1,1 ml 2 times a week during 5…10 weeks, Limphomyosot per os for 2…3 drops 3 times a day during 3 months, Spascupreeli for 1 suppository before going to bed during 10…20 days, Nevroheeli for 1/4 tablet 3 times a day during 2…3 months, Traumeli C intramuscularly for 0,6…1,1 ml 2 times a week, to a course of treatment 5…10 injections, Coenzyme Compozitum intramuscularly for 0,5…1,0 ml once a week, to a course of treatment 3…5 injections, Ubichinoni Compositum intramuscularly for 0,5…1,0 ml once a week, to a course of treatment 3…5 injections, Placenta Compositum intramuscularly for 0,5…1,0 ml once a week, to a course of treatment 3…5 injections. The course of treatment is repeated 2…3 times in 2…4 months.
MDA20060252A 2006-10-27 2006-10-27 Method of treating the organic central nervous system lesions to infants MD3341G2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20060252A MD3341G2 (en) 2006-10-27 2006-10-27 Method of treating the organic central nervous system lesions to infants

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20060252A MD3341G2 (en) 2006-10-27 2006-10-27 Method of treating the organic central nervous system lesions to infants

Publications (2)

Publication Number Publication Date
MD3341F1 MD3341F1 (en) 2007-06-30
MD3341G2 true MD3341G2 (en) 2008-01-31

Family

ID=38229408

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20060252A MD3341G2 (en) 2006-10-27 2006-10-27 Method of treating the organic central nervous system lesions to infants

Country Status (1)

Country Link
MD (1) MD3341G2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD966Z (en) * 2015-01-29 2016-06-30 Штефан ГАЦКАН Method for predicting the risk of development of congenital pathology of the central nervous system in the fetus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1286206A1 (en) * 1984-07-18 1987-01-30 Ташкентский государственный медицинский институт Method of treatment of perinatal encelophalopathy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1286206A1 (en) * 1984-07-18 1987-01-30 Ташкентский государственный медицинский институт Method of treatment of perinatal encelophalopathy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD966Z (en) * 2015-01-29 2016-06-30 Штефан ГАЦКАН Method for predicting the risk of development of congenital pathology of the central nervous system in the fetus

Also Published As

Publication number Publication date
MD3341F1 (en) 2007-06-30

Similar Documents

Publication Publication Date Title
MX2011007854A (en) Methods for treating acute myocardial infarctions and associated disorders.
WO2008039898A3 (en) Methods for the treatment of a traumatic central nervous system injury
BR112015012497A2 (en) pharmaceutical combinations
JP2013520447A5 (en)
MD3341G2 (en) Method of treating the organic central nervous system lesions to infants
ATE506941T1 (en) TREATMENT OF PSYCHIATRIC PATIENTS WITH SLEEP DISORDERS AND/OR EXCESSIVE DAYTIME SLEEPING WITH PALIPERIDONE
ZA202500495B (en) Pharmaceutical composition of anti-cd20 antibody and use thereof
MD3803G2 (en) Method of treating hyperkinesia of children
RU2015155001A (en) DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE WITH THE USE OF ANNEXINS LABELED WITH RADIONUCLIDE
Kim et al. Non-Eczematous Vesiculobullous Skin Eruption after Stevens-Johnson Syndrome: Developed without Intravenous Immunoglobulin Therapy
Wisniewski P01-366-New treatment option in resistant schizophrenia in adolescence-case study
Češková Léčba farmakorezistentních stavů v psychiatrii-1. část: Farmakorezistentní schizofrenie.
MD10Z (en) Method for treating the gestational pyelonephritis
Hori Celecoxib/fluvoxamine interaction
Williams Nausea and headache: case report
MX2023005899A (en) Cyclobenzaprine treatment for alcohol use disorder.
Lang et al. Convulsive status epilepticus after electroconvulsive therapy
MD2827G2 (en) method of prophylaxis of the dishormonal mammary hyperplasiae
Knop et al. Bortezomib Once Weekly Is Well Tolerated as Maintenance Therapy after Less Than a Complete Response to High-Dose Melphalan in Patients with Multiple Myeloma.
Salvi Role of the anti-CD20 antibody Rituximab in Graves’ disease
MD596Y (en) Method for treating the chronic viral hepatitis C
Kozumplik et al. SAME MEDICATIONS OR DIFFERENT?
Cisneros Serrano Omalizumab/prednisone
Maniscalco Paroxetine/rhodiola rosea interaction
Watras Clozapine/fluvoxamine

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees